肿瘤坏死因子α抑制剂治疗化脓性汗腺炎四例

doi:10.35541/cjd.20200647

摘要/Abstract

摘要： 【摘要】报道2017年8月至2019年12月第四军医大学西京皮肤医院收治的4例化脓性汗腺炎，年龄20 ~ 45岁，均为男性，皮损表现为腋窝、臀部、腹股沟的窦道、脓肿、瘢痕，Hurley分期Ⅱ~Ⅲ期。既往使用抗生素、糖皮质激素、维A酸类药物、中药等多种治疗方案，改善均不明显。予静脉滴注英夫利西单抗5 mg/kg，第0、2、6周各1次，后每间隔8周1次；或皮下注射阿达木单抗，第0、2周各80 mg/次，后每间隔2周40 mg/次。2例静脉滴注英夫利西单抗后出现输液反应，改用阿达木单抗。3例达到化脓性汗腺炎临床反应（HiSCR），1例无效。

关键词: 化脓性汗腺炎, 生物制剂, 治疗, 英夫利西单抗, 阿达木单抗

Abstract: 【Abstract】 Four male cases of hidradenitis suppurativa (Hurley stage Ⅱ/Ⅲ) aged 20 - 45 years were collected from Department of Dermatology, Xijing Hospital, the Fourth Military Medical University from August 2017 to December 2019. All the patients presented with sinuses, abscesses and scars on the buttocks, axillary and inguinal regions, and showed a poor response to previous treatment with antibiotics, glucocorticoids, retinoids, traditional Chinese medicine, etc. The patients were treated with intravenous drips of infliximab at a dose of 5 mg/kg at weeks 0, 2 and 6, followed by an every-9-week treatment regimen, or with subcutaneous injection of adalimumab at a dose of 80 mg at weeks 0 and 2, followed by an every-3-week regimen at a dose of 40 mg. Two patients experienced infusion reactions after intravenous drips of infliximab, and then were switched to adalimumab. Three of these patients achieved hidradenitis suppurativa clinical response （HiSCR）, whereas 1 showed no response.

Key words: Hidradenitis suppurativa, Biological agents, Treatment, Infliximab, Adalimumab

师蓓朱冠男付萌. 肿瘤坏死因子α抑制剂治疗化脓性汗腺炎四例[J]. 中华皮肤科杂志, 2021, 54(10): 901-903.doi:10.35541/cjd.20200647

Shi Bei, Zhu Guannan, Fu Meng. Tumor necrosis factor-α inhibitors for the treatment of four cases of hidradenitis suppurativa[J]. Chinese Journal of Dermatology, 2021, 54(10): 901-903.doi:10.35541/cjd.20200647

参考文献 10

［1］	Mekkes JR, Bos JD. Long⁃term efficacy of a single course of infliximab in hidradenitis suppurativa［J］. Br J Dermatol, 2008,158（2）:370⁃374. doi: 10.1111/j.1365⁃2133.2007.08332.x.
［2］	Sotiriou E, Goussi C, Lallas A, et al. A prospective open⁃label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa［J］. J Drugs Dermatol, 2012,11（5 Suppl）:s15⁃s20.
［3］	Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:619⁃644. doi: 10. 1111/jdv.12966.
［4］	Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis,hidradenitis suppurativa, and familial benign pemphigus: surgical approach［M］//Roenigh R, Roenigh H. Dermatologic Surgery. New York: Marcel Dekker, 1989:729⁃739.
［5］	Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response （HiSCR） as the clinical endpoint for hidradenitis suppurativa treatment［J］. Br J Dermatol, 2014,171（6）:1434⁃1442. doi: 10.1111/bjd.13270.
［6］	van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor （TNF）⁃α, interleukin （IL）⁃1β and IL⁃10 in hidradenitis suppurativa skin: a rationale for targeting TNF⁃α and IL⁃1β［J］. Br J Dermatol, 2011,164（6）:1292⁃1298. doi: 10.1111/j.1365⁃2133.2011.10254.x.
［7］	Lesage C, Adnot⁃Desanlis L, Perceau G, et al. Efficacy and tolerance of prolonged infliximab treatment of moderate⁃to⁃severe forms of hidradenitis suppurativa［J］. Eur J Dermatol, 2012,22（5）:640⁃644. doi: 10.1684/ejd.2012.1795.
［8］	Delage M, Samimi M, Atlan M, et al. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers［J］. Acta Derm Venereol, 2011,91（2）:169⁃171. doi: 10.2340/00015555⁃1025.
［9］	Miller I, Lynggaard CD, Lophaven S, et al. A double⁃blind placebo⁃controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa［J］. Br J Dermatol, 2011,165（2）:391⁃398. doi: 10.1111/j.1365⁃2133.2011.10339.x.
［10］	Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial［J］. Ann Intern Med, 2012,157（12）:846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004.

[1]	邱月棨付思祺罗帅寒天李亚萍张桂英. 2020年雄激素性脱发的研究进展[J]. 中华皮肤科杂志, 2021, 54(9): 835-838.
[2]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[3]	中华医学会医学美学与美容学分会激光美容学组中华医学会皮肤性病学分会美容激光学组中国医师协会美容与整形医师分会激光学组. 中国痤疮瘢痕治疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 747-756.
[4]	中华医学会皮肤性病学分会皮肤肿瘤研究中心中国医师协会皮肤科医师分会皮肤肿瘤学组. 皮肤基底细胞癌诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(9): 757-764.
[5]	郭伟赵涛郭伟楠马翠玲高天文赵建红李冰. 早期甲黑素瘤115例手术治疗方案和预后回顾分析[J]. 中华皮肤科杂志, 2021, 54(9): 777-784.
[6]	王大光蒋佳怡. 几种甲病诊疗的思考[J]. 中华皮肤科杂志, 2021, 54(8): 733-737.
[7]	宋歌梁官钊张美洁董嘉琤刘维达. 毳毛癣的临床诊治进展[J]. 中华皮肤科杂志, 2021, 54(8): 741-743.
[8]	虞英媛李影余增洋郑建锋张希琳丁杨峰史玉玲. 英夫利西单抗治疗重度斑块状银屑病的疗效和安全性及其对PD-1、PD-L1表达的影响[J]. 中华皮肤科杂志, 2021, 54(7): 590-596.
[9]	张宇高迎霞顾宁琰朱虹陈京京胡清洁周敏段媛媛姚煦. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析[J]. 中华皮肤科杂志, 2021, 54(7): 582-585.
[10]	中华医学会皮肤性病学分会银屑病学组中华医学会皮肤性病学分会儿童学组. 中国儿童银屑病诊疗专家共识（2021）[J]. 中华皮肤科杂志, 2021, 54(7): 559-581.
[11]	曹珊杨宝琦. 疱疹样皮炎的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 549-553.
[12]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[13]	中国医疗保健国际交流促进会皮肤科分会. 女阴硬化性苔藓诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 371-375.
[14]	李文锐贾苇雪张蕴斌林麟李诚让. nicastrin基因沉默的斑马鱼模型构建及其色素异常机制的初步研究[J]. 中华皮肤科杂志, 2021, 54(5): 402-407.
[15]	张锡宝董良娇叶瑞贤刘焕颜熊绮颖. 老年特应性皮炎[J]. 中华皮肤科杂志, 2021, 54(5): 447-451.